An update on CEL-SCI’s arbitration with its former clinical research organisation (CRO) has been announced.
Legal
Last week, the final witness in the arbitration hearing gave their testimony, leading to the conclusion of the testimony phase of the arbitration. Closing statements and post-trial submissions remain at trial level for this case.
CEL-SCI filed an arbitration in 2013, seeking $50 million from its former CRO that used to run the Company’s Phase III head and neck cancer study with Multikine. The arbitration claim brought forward by CEL-SCI alleges that there was (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. The CRO was replaced in 2013.
Multikine (Leukocyte Interleukin, Injection) is CEL-SCI’s lead investigational immunotherapy that is currently being studied in a pivotal Phase III clinical trial as a potential neoadjuvant treatment in patients with squamous cell carcinoma of the head and neck.